Conclusions
In a contemporary cohort of children from Florida with HM, we found that
B children had an increased likelihood of receiving an HLA-mismatched
donor HCT, and in particular a mismatched related donor transplant.
HLA-matching significantly affected 2-year survival among W but not
among B HCT recipients. Despite increased use of mismatched donors,
overall survival, incidence of GVHD and causes of death did not differ
between W and B children receiving HCT for hematologic malignancies.